1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > B-Cell Lymphomas – Pipeline Review, H1 2013

B-Cell Lymphomas – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 580 pages

B-Cell Lymphomas – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Lymphomas. B-Cell Lymphomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Lymphomas.
- A review of the B-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Lymphomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Lymphomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

B-Cell Lymphomas - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 7
B-Cell Lymphomas Overview 8
Therapeutics Development 9
B-Cell Lymphomas Therapeutics under Development by Companies 11
B-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Mid Clinical Stage Products 22
Early Clinical Stage Products 23
Discovery and Pre-Clinical Stage Products 24
B-Cell Lymphomas Therapeutics - Products under Development by Companies 25
B-Cell Lymphomas Therapeutics - Products under Investigation by Universities/Institutes 34
Companies Involved in B-Cell Lymphomas Therapeutics Development 37
B-Cell Lymphomas - Therapeutics Assessment 110
Drug Profiles 117
B-Cell Lymphomas Therapeutics - Drug Profile Updates 429
B-Cell Lymphomas Therapeutics - Discontinued Products 543
B-Cell Lymphomas Therapeutics - Dormant Products 545
B-Cell Lymphomas - Product Development Milestones 552
Appendix 561

List of Tables

Number of Products Under Development for B-Cell Lymphomas, H1 2013 27
Products under Development for B-Cell Lymphomas - Comparative Analysis, H1 2013 28
Number of Products under Development by Companies, H1 2013 30
Number of Products under Development by Companies, H1 2013 (Contd..1) 31
Number of Products under Development by Companies, H1 2013 (Contd..2) 32
Number of Products under Development by Companies, H1 2013 (Contd..3) 33
Number of Products under Development by Companies, H1 2013 (Contd..4) 34
Number of Products under Development by Companies, H1 2013 (Contd..5) 35
Number of Products under Investigation by Universities/Institutes, H1 2013 37
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 38
Comparative Analysis by Late Stage Development, H1 2013 39
Comparative Analysis by Mid Clinical Stage Development, H1 2013 40
Comparative Analysis by Early Clinical Stage Development, H1 2013 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 42
Products under Development by Companies, H1 2013 43
Products under Development by Companies, H1 2013 (Contd..1) 44
Products under Development by Companies, H1 2013 (Contd..2) 45
Products under Development by Companies, H1 2013 (Contd..3) 46
Products under Development by Companies, H1 2013 (Contd..4) 47
Products under Development by Companies, H1 2013 (Contd..5) 48
Products under Development by Companies, H1 2013 (Contd..6) 49
Products under Development by Companies, H1 2013 (Contd..7) 50
Products under Development by Companies, H1 2013 (Contd..8) 51
Products under Investigation by Universities/Institutes, H1 2013 52
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 53
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 54
Bristol-Myers Squibb Company, H1 2013 55
Johnson and Johnson, H1 2013 56
Boehringer Ingelheim GmbH, H1 2013 57
F. Hoffmann-La Roche Ltd., H1 2013 58
Kyowa Hakko Kirin Co., Ltd., H1 2013 59
Biogen Idec Inc., H1 2013 60
Amgen Inc., H1 2013 61
Sanofi-Aventis, H1 2013 62
AstraZeneca PLC, H1 2013 63
Eli Lilly and Company, H1 2013 64
GlaxoSmithKline plc, H1 2013 65
Seattle Genetics, Inc., H1 2013 66
Genentech, Inc., H1 2013 67
MedImmune LLC, H1 2013 68
Gilead Sciences, Inc., H1 2013 69
Merck and Co., Inc., H1 2013 70
Emergent BioSolutions Inc., H1 2013 71
Lentigen Corporation, H1 2013 72
Infinity Pharmaceuticals, Inc., H1 2013 73
Reliance Life Sciences Pvt. Ltd., H1 2013 74
Celltrion, Inc., H1 2013 75
Millennium Pharmaceuticals, Inc., H1 2013 76
Novartis AG, H1 2013 77
Astellas Pharma Inc., H1 2013 78
Glenmark Pharmaceuticals Ltd., H1 2013 79
Ono Pharmaceutical Co., Ltd., H1 2013 80
Pfizer Inc., H1 2013 81
SuperGen, Inc., H1 2013 82
Teva Pharmaceutical Industries Limited, H1 2013 83
Cell Therapeutics, Inc., H1 2013 84
Genmab A/S, H1 2013 85
Sandoz Inc., H1 2013 86
Celgene Corporation, H1 2013 87
Onyx Pharmaceuticals, Inc., H1 2013 88
Bayer AG, H1 2013 89
Merck KGaA, H1 2013 90
Celldex Therapeutics, Inc., H1 2013 91
AEterna Zentaris Inc., H1 2013 92
IMMUNOMEDICS, INC, H1 2013 93
Idera Pharmaceuticals, Inc., H1 2013 94
Marshall Edwards, Inc., H1 2013 95
MethylGene Inc, H1 2013 96
Curis, Inc., H1 2013 97
Accentia Biopharmaceuticals, Inc., H1 2013 98
Portola Pharmaceuticals, Inc., H1 2013 99
Telik, Inc., H1 2013 100
Mundipharma International Limited, H1 2013 101
Pharmacyclics, Inc., H1 2013 102
Green Cross Corporation, H1 2013 103
Spectrum Pharmaceuticals, Inc., H1 2013 104
Memgen, LLC., H1 2013 105
Abiogen Pharma S.p.A., H1 2013 106
Provenance Biopharmaceuticals Corp., H1 2013 107
Celentyx Ltd., H1 2013 108
Fresenius Biotech GmbH, H1 2013 109
Semafore Pharmaceuticals, Inc., H1 2013 110
Stemline Therapeutics, Inc., H1 2013 111
Onconova Therapeutics, Inc, H1 2013 112
Immune System Therapeutics Ltd., H1 2013 113
Mirna Therapeutics, Inc., H1 2013 114
Xencor, Inc., H1 2013 115
CureTech Ltd., H1 2013 116
Cylene Pharmaceuticals, Inc., H1 2013 117
Dynamix Pharmaceuticals Ltd., H1 2013 118
Cancer Therapeutics CRC Pty Ltd, H1 2013 119
Areta International s.r.l., H1 2013 120
Helmholtz Zentrum München, GmbH, H1 2013 121
Synthon BV, H1 2013 122
Shanghai CP Guojian Pharmaceutical Co.,Ltd., H1 2013 123
PharmaTech International, Inc., H1 2013 124
Cell>Point, H1 2013 125
Coridon Pty Ltd, H1 2013 126
Advancell, H1 2013 127
Assessment by Monotherapy Products, H1 2013 128
Assessment by Combination Products, H1 2013 129
Assessment by Stage and Route of Administration, H1 2013 131
Assessment by Stage and Molecule Type, H1 2013 134
B-Cell Lymphomas Therapeutics - Drug Profile Updates 446
B-Cell Lymphomas Therapeutics - Discontinued Products 560
B-Cell Lymphomas Therapeutics - Discontinued Products (Contd..1) 561
B-Cell Lymphomas Therapeutics - Dormant Products 562
B-Cell Lymphomas Therapeutics - Dormant Products (Contd..1) 563
B-Cell Lymphomas Therapeutics - Dormant Products (Contd..2) 564
B-Cell Lymphomas Therapeutics - Dormant Products (Contd..3) 565
B-Cell Lymphomas Therapeutics - Dormant Products (Contd..4) 566
B-Cell Lymphomas Therapeutics - Dormant Products (Contd..5) 567
B-Cell Lymphomas Therapeutics - Dormant Products (Contd..6) 568

List of Figures

Number of Products under Development for B-Cell Lymphomas, H1 2013 27
Products under Development for B-Cell Lymphomas - Comparative Analysis, H1 2013 28
Products under Development by Companies, H1 2013 29
Products under Investigation by Universities/Institutes, H1 2013 36
Late Stage Products, H1 2013 39
Mid Clinical Stage Products, H1 2013 40
Early Clinical Stage Products, H1 2013 41
Discovery and Pre-Clinical Stage Products, H1 2013 42
Assessment by Monotherapy Products, H1 2013 128
Assessment by Combination Products, H1 2013 129
Assessment by Route of Administration, H1 2013 130
Assessment by Stage and Route of Administration, H1 2013 131
Assessment by Molecule Type, H1 2013 132
Assessment by Stage and Molecule Type, H1 2013 133

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.